New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells

Biochemical Pharmacology

Volumn 95, Issue 3, 2015, Pages 133-144

  Novohradsky, Vojtech ^a   Zerzankova, Lenka ^a   Stepankova, Jana ^a   Vrana, Oldrich ^a   Raveendran, Raji ^b   Gibson, Dan ^b   Kasparkova, Jana ^c   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Cellular accumulation; Chromatin decondensation; Cytotoxicity; Glutathione; Histone deacetylase inhibition; Platinum valproic acid conjugates

Indexed keywords

GLUTATHIONE; HISTONE; HISTONE DEACETYLASE; PLATINUM COMPLEX; VALPROIC ACID;

ACETYLATION; CHEMISTRY; FEMALE; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ACETYLATION; CELL LINE, TUMOR; EPIGENESIS, GENETIC; FEMALE; GLUTATHIONE; HISTONE DEACETYLASES; HISTONES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; VALPROIC ACID;

EID: 84936756705     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.04.003     Document Type: Article

References (50)

1. L. Kelland The resurgence of platinum-based cancer chemotherapy Nature Rev. Cancer 7 2007 573 584
2. M.A. Fuertes, J. Castilla, C. Alonso, and J.M. Perez Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways Curr. Med. Chem. 10 2003 257 266
3. D.C. Marchion, E. Bicaku, A.I. Daud, V. Richon, D.M. Sullivan, and P.N. Munster Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid J. Cell. Biochem. 92 2004 223 237
4. M.S. Kim, M. Blake, J.H. Baek, G. Kohlhagen, Y. Pommier, and F. Carrier Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Res. 63 2003 7291 7300
5. H.V.K. Diyabalanage, M.L. Granda, and J.M. Hooker Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer Cancer Lett. 329 2013 1 8
6. C.M. Giandomenico, M.J. Abrams, B.A. Murrer, J.F. Vollano, M.I. Rheinheimer, and S.B. Wyer Carboxylation of kinetically inert platinum(IV) hydroxy complexes - an entree into orally-active platinum(IV) antitumor agents Inorg. Chem. 34 1995 1015 1021
7. S. Dhar, F.X. Gu, R. Langer, O.C. Farokhzad, and S.J. Lippard Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. U.S.A. 105 2008 17356 17361
8. S. Dhar, Z. Liu, J. Thomale, H.J. Dai, and S.J. Lippard Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device J. Am. Chem. Soc. 130 2008 11467 11476
9. S. Mukhopadhyay, C.M. Barnes, A. Haskel, S.M. Short, K.R. Barnes, and S.J. Lippard Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature Bioconjugate Chem. 19 2008 39 49
10. J. Yang, X. Sun, W. Mao, M. Sui, J. Tang, and Y. Shen Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy Mol. Pharm. 9 2012 2793 2800
11. M. Alessio, I. Zanellato, I. Bonarrigo, E. Gabano, M. Ravera, and D. Osella Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells J. Inorg. Biochem. 129 2013 52 57
12. E. Jasek, G.J. Lis, M. Jasinska, H. Jurkowska, and J.A. Litwin Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells Anticancer Res. 32 2012 2791 2799
13. B. Tsolmongyn, N. Koide, E. Odkhuu, A. Haque, Y. Naiki, and T. Komatsu Lipopolysaccharide prevents valproic acid-induced apoptosis via activation of nuclear factor-kappa B and inhibition of p53 activation Cell. Immunol. 282 2013 100 105
14. M. Gottlicher, S. Minucci, P. Zhu, O.H. Kramer, A. Schimpf, and S. Giavara Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J. 20 2001 6969 6978
15. J.A. Bermudez-Lugo, O. Perez-Gonzalez, M.C. Rosales-Hernandez, I. Ilizaliturri-Flores, J. Trujillo-Ferrara, and J. Correa-Basurto Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations J. Mol. Model. 18 2012 2301 2310
16. P. Kwiecinska, A. Wrobel, E. Tauboll, and E.L. Gregoraszczuk Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells Toxicol. Lett. 224 2014 225 232
17. A.J. Frew, R.W. Johnstone, and J.E. Bolden Enhancing the apoptotic and therapeutic effects of HDAC inhibitors Cancer Lett. 280 2009 125 133
18. H-J. Kim, and S-C. Bae Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs Am. J. Transl. Res. 3 2011 166 179
19. J.Z. Zhang, P. Bonnitcha, E. Wexselblatt, A.V. Klein, Y. Najajreh, and D. Gibson Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design Chem. Eur. J. 19 2013 1672 1676
20. C. Moser, S.A. Lang, S. Kainz, A. Gaumann, S. Fichtner-Feigl, and G.E. Koehl Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo Mol. Cancer Ther. 6 2007 2868 2878
21. I. Zanellato, I. Bonarrigo, E. Gabano, M. Ravera, N. Margiotta, and P.G. Betta Metallo-drugs in the treatment of malignant pleural mesothelioma Inorg. Chim. Acta 393 2012 64 74
22. L.R. Kelland, C.F.J. Barnard, K.J. Mellish, M. Jones, P.M. Goddard, and M. Valenti A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity Cancer Res. 54 1994 5618 5622
23. L.R. Kelland, S.Y. Sharp, C.F. O.Neill, F.I. Raynaud, P.J. Beale, and I.R. Judson Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance J. Inorg. Biochem. 77 1999 111 115
24. S.J. Fan, M.L. Smith, D.J. Rivet, D. Duba, Q.M. Zhan, and K.W. Kohn Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline Cancer Res. 55 1995 1649 1654
25. K. Suntharalingam, Y. Song, and S.J. Lippard Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy Chem. Commun. 50 2014 2465 2468
26. O.H. Kramer, P. Zhu, H.P. Ostendorff, M. Golebiewski, J. Tiefenbach, and M.A. Peters The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 EMBO J. 22 2003 3411 3420
27. V.L. Nelson-DeGrave, J.K. Wickenheisser, J.E. Cockrell, J.R. Wood, R.S. Legro, and J.F. Strauss Valproate potentiates androgen biosynthesis in human ovarian theca cells Endocrinology 145 2004 799 808
28. Q. Xia, J. Sung, W. Chowdhury, N. Chen C-l Hoti, and S. Shabbeer Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo Cancer Res. 66 2006 7237 7244
29. K. Tikoo, I.Y. Ali, J. Gupta, and C. Gupta 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats Toxicol. Lett. 191 2009 158 166
30. M. Koprinarova, P. Markovska, I. Iliev, B. Anachkova, and G. Russev Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest BMC Mol. Biol. 11 2010 49
31. -2H)] Mol. Pharm. 9 2012 1990 1999
32. F. Oberhammer, G. Fritsch, M. Schmied, M. Pavelka, D. Printz, and T. Purchio Condensation of the chromatin at the membrane of an apoptotic nucleus is not associated with activation of an endonuclease J. Cell. Sci. 104 1993 317 326
33. T.K.L. Kiang, X.W. Teng, J. Surendradoss, S. Karagiozov, F.S. Abbott, and T.K.H. Chang Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: Role of biotransformation and temporal relationship with onset of toxicity Toxicol. Appl. Pharmacol. 252 2011 318 324
34. D. Han, N. Hanawa, B. Saberi, and N. Kaplowitz Mechanisms of liver injury. III. Role of glutathione redox status in liver injury Am. J. Physiol. Gastrointest. Liver Physiol. 291 2006 G1 G7
35. X. Wang, and Z. Guo The role of sulfur in platinum anticancer chemotherapy Anti-Cancer Agents Med. Chem. 7 2007 19 34
36. E.R. Jamieson, and S.J. Lippard Structure, recognition, and processing of cisplatin-DNA adducts Chem. Rev. 99 1999 2467 2498
37. M.A. Fuertes, C. Alonso, and J.M. Perez Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance Chem. Rev. 103 2003 645 662
38. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nature Rev. Drug Discov. 4 2005 307 320
39. S.Y. Loh, P. Mistry, L.R. Kelland, G. Abel, and K.R. Harrap Reduced drug accumulation as a major mechanism of acquired-resistance to cisplatin in a human ovarian-carcinoma cell-line. Circumvention studies using novel platinum (II) and (IV) ammine amine complexes Br. J. Cancer 66 1992 1109 1115
40. S.P. Oldfield, M.D. Hall, and J.A. Platts Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake J. Med. Chem. 50 2007 5227 5237
41. M-G. Mendoza-Ferri, C.G. Hartinger, R.E. Eichinger, N. Stolyarova, K. Severin, and M.A. Jakupec Influence of the spacer length on the in vitro anticancer activity of dinuclear ruthenium-arene compounds Organometallics 27 2008 2405 2407
42. P. Gramatica, E. Papa, M. Luini, E. Monti, M. Gariboldi, and M. Ravera Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure-activity relationship modeling J. Biol. Inorg. Chem. 15 2010 1157 1169
43. Z. Liu, L. Salassa, A. Habtemariam, A.M. Pizarro, G.J. Clarkson, and P.J. Sadler Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes Inorg. Chem. 50 2011 5777 5783
44. N. Terbach, R. Shah, R. Kelemen, P.S. Klein, D. Gordienko, and N.A. Brown Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid using the simple biomedical model Dictyostelium J. Cell Sci. 124 2011 2267 2276
45. D.M. Fass, R. Shah, B. Ghosh, K. Hennig, S. Norton, and W-N. Zhao Short-chain HDAC inhibitors differentially affect vertebrate development and neuronal chromatin ACS Med. Chem. Lett. 2 2011 39 42
46. L. Cincarova, G. Lochmanova, K. Novakova, P. Sultesova, H. Konecna, and L. Fajkusova A combined approach for the study of histone deacetylase inhibitors Mol. BioSyst. 8 2012 2937 2945
47. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541 5552
48. C.S. Ward, P. Eriksson, J.L. Izquierdo-Garcia, A.H. Brandes, and S.M. Ronen HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells PLoS One 2013 2013
49. G. Alcarraz-Vizan, J. Boren, W.N.P. Lee, and M. Cascante Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation Metabolomics 6 2010 229 237
50. E. Gabano, M. Ravera, and D. Osella Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one Dalton Trans. 43 2014 9813 9820